Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system
2024 · The Journal of Dermatology · 7 citations
https://doi.org/10.1111/1346-8138.17517